These shares are ending the week in the red. But why? The post Why Appen, Brainchip, Liontown, and Mesoblast shares are ...

Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

Mesoblast Limited (NASDAQ:MESO – Get Free Report)’s share price hit a new 52-week high on Monday . The stock traded as high ...

These shares are starting the year in a positive fashion. But why? The post Why Brainchip, Fortescue, Mesoblast, and QBE ...

Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the U.S. Ryoncil is the only MSC therapy ...

Mesoblast Limited (AU:MSB) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street ...

The Weebit Nano share price is up 4% to $3.60. This gain comes despite there being no news out of the semiconductor company.

Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...

Mesoblast has gained US Food and Drug Administration (FDA) approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil ...

Remestemcel-L is under clinical development by Mesoblast and currently in Phase III for Crohn's Disease (Regional Enteritis).